Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ACTIVATED CLOTTING TIME' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 103 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Smith, TT; Labriola, R
      Developing best practice in arterial sheath removal for registered nurses

      JOURNAL OF NURSING CARE QUALITY
    2. Schroeder, AP; Knudsen, LL; Husted, SE; Knudsen, L; Ingerslev, J
      Bedside coagulometry during intravenous heparin therapy after coronary angioplasty

      JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    3. Tsimikas, S; Beyer, R; Hassankhani, A
      Relationship between the heparin management test and the HemoTec activatedclotting time in patients undergoing percutaneous coronary intervention

      JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    4. Hodoglugil, U; Gunaydin, B; Yardim, S; Zengil, H; Smolensky, MH
      Seasonal variation in the effect of a fixed dose of heparin on activated clotting time in patients prepared for open-heart surgery

      CHRONOBIOLOGY INTERNATIONAL
    5. Brinks, HJ; Weerwind, PW; Bogdan, S; Verbruggen, H; Brouwer, MHJ
      Does heparin pretreatment affect the haemostatic system during and after cardiopulmonary bypass?

      PERFUSION-UK
    6. Ambrose, TM; Parvin, CA; Mendeloff, E; Luchtman-Jones, L
      Evaluation of the TAS analyzer and the low-range heparin management test in patients undergoing extracorporeal membrane oxygenation

      CLINICAL CHEMISTRY
    7. Godon, P; Rioufol, G; Finet, G; Chirossel, P; de Gevigney, GD; Roriz, R; Rossi, R; Fouet, XA; Bonnefoy, E; Mc Fadden, EP
      Efficacy and safety of low dose heparin (30 IU/Kg) during coronary angioplasty

      ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX
    8. Levy, JH
      Pharmacologic preservation of the hemostatic system during cardiac surgery

      ANNALS OF THORACIC SURGERY
    9. Heindel, SW; Mill, MR; Freid, EB; Valley, RD; White, GC; Norfleet, EA
      Fatal thrombosis associated with a hemi-Fontan procedure, heparin-protamine reversal, and aprotinin

      ANESTHESIOLOGY
    10. Heres, EK; Horrow, JC; Gravlee, GP; Tardiff, BE; Luber, J; Schneider, J; Barragry, T; Broughton, R
      A dose-determining trial of heparinase-I (Neutralase (TM)) for heparin neutralization in coronary artery surgery

      ANESTHESIA AND ANALGESIA
    11. Griffin, MJ; Rinder, HM; Smith, BR; Tracey, JB; Kriz, NS; Li, CK; Rinder, CS
      The effects of heparin, protamine, and heparin/protamine reversal on platelet function under conditions of arterial shear stress

      ANESTHESIA AND ANALGESIA
    12. Dietrich, W; Braun, S; Spannagl, M; Richter, JA
      Low preoperative antithrombin activity causes reduced response to heparin in adult but not in infant cardiac-surgical patients

      ANESTHESIA AND ANALGESIA
    13. Levy, JP
      Novel intravenous antithrombins

      AMERICAN HEART JOURNAL
    14. Vahdat, B; Canavy, I; Fourcade, L; Garcia, E; Quilici, J; Bonnet, JL; Bory, M
      Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    15. Kereiakes, DJ; Broderick, TM; Abbottsmith, C; Shimshak, TM
      Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: A new look at an old problem

      JOURNAL OF INVASIVE CARDIOLOGY
    16. Kereiakes, DJ; Fry, E; Matthai, W; Niederman, A; Barr, L; Brodie, B; Zidar, J; Casale, P; Christy, G; Moliterno, D; Lengerich, R; Broderick, T; Shimshak, T; Cohen, M
      Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first"

      JOURNAL OF INVASIVE CARDIOLOGY
    17. Koestenberger, M; Gallistl, S; Cvirn, G; Roschitz, B; Muntean, W
      Effects of the glycoprotein IIb/IIIa receptor antagonist c7E3 Fab and anticoagulants on platelet aggregation and thrombin potential under high coagulant challenge in vitro

      BLOOD COAGULATION & FIBRINOLYSIS
    18. Li, YF; Spencer, FA; Ball, S; Becker, RC
      Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: Potential contributing mechanism of benefit in acute coronary syndromes

      JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    19. Miyashita, T; Nakajima, T; Hayashi, Y; Kuro, M
      Hemostatic effects of low-dose protamine following cardiopulmonary bypass

      AMERICAN JOURNAL OF HEMATOLOGY
    20. Furman, MI; Krueger, LA; Frelinger, AL; Barnard, MR; Mascelli, MA; Nakada, MT; Michelson, AD
      GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood

      THROMBOSIS AND HAEMOSTASIS
    21. Codispoti, M; Mankad, PS
      Management of anticoagulation and its reversal during paediatric cardiopulmonary bypass: a review of current UK practice

      PERFUSION-UK
    22. Girardi, L; Sudi, K; Muntean, W
      Effect of heparin, platelets, activated platelets, platelet fragments, andhematocrit on activated clotting time

      ARTIFICIAL ORGANS
    23. Shirota, K; Watanabe, T; Takagi, Y; Ohara, Y; Usui, A; Yasuura, K
      Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonarybypass

      ARTIFICIAL ORGANS
    24. Lemmer, JH
      Clinical experience in coronary bypass surgery for abciximab-treated patients

      ANNALS OF THORACIC SURGERY
    25. Lemmer, JH; Metzdorff, MT; Krause, AH; Martin, MA; Okies, JE; Hill, JG
      Emergency coronary artery bypass graft surgery in abciximab-treated patients

      ANNALS OF THORACIC SURGERY
    26. Mertzlufft, F; Koster, A; Hansen, R; Risch, A; Kuppe, H; Kubel, B; Crystal, GJ
      Reliability of the heparin management test for monitoring high levels of unfractionated heparin - In vitro findings in volunteers versus in vivo findings during cardiopulmonary bypass

      ANESTHESIOLOGY
    27. Shore-Lesserson, L; Manspeizer, HE; Bolastig, M; Harrington, D; Vela-Cantos, F; DePerio, M
      Anticoagulation for cardiac surgery in patients receiving preoperative heparin: Use of the high-dose thrombin time

      ANESTHESIA AND ANALGESIA
    28. Ambrose, JA; Hawkey, M; Badimon, JJ; Coppola, J; Geagea, JP; Rentrop, KP; Domiguez, A; Duvvuri, S; Elmquist, T; Arias, J; Doss, R; Dangas, G
      In vivo demonstration of an antithrombin effect of Abciximab

      AMERICAN JOURNAL OF CARDIOLOGY
    29. Kuiper, KKJ; Nordrehaug, JE
      Early mobilization after protamine reversal of heparin following implantation of phosphorylcholine-coated stents in totally occluded coronary arteries

      AMERICAN JOURNAL OF CARDIOLOGY
    30. Zeevi, B; Bar-Mor, G; Livne, M; Berant, M
      A comparison of arterial versus venous-activated clotting time in patientswith congenital heart disease undergoing cardiac catheterization

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    31. Kohrs, R; Hoenemann, CW; Feirer, N; Durieux, ME
      Bupivacaine inhibits whole blood coagulation in vitro

      REGIONAL ANESTHESIA AND PAIN MEDICINE
    32. Alvarez, JM; Chandraratna, H; Newman, MAJ; Levy, JH
      Intraoperative coronary thrombosis in association with low-dose aprotinin therapy

      JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
    33. Levy, JH
      Hemostatic agents and their safety

      JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
    34. Despotis, GJ; Joist, JH
      Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: An update

      JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
    35. Fitch, JCK; Geary, KLB; Mirto, GP; Byrne, DW; Hines, RL
      Heparin management test versus activated coagulation time during cardiovascular surgery: Correlation with anti-Xa activity

      JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
    36. Berlis, A; Schumacher, M
      Anticoagulation control with ACT (activated clotting time) during interventional neuroradiology.

      ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN
    37. Rabah, M; Mason, D; Muller, DWM; Hundley, R; Kugelmass, AD; Weiner, B; Cannon, L; O'Neill, WW; Safian, RD
      Heparin after percutaneous intervention (HAPI): A prospective multicenter randomized trial of three heparin regimens after successful coronary intervention

      JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    38. Ranucci, M; Isgro, G; Cazzaniga, A; Soro, G; Menicanti, L; Frigiola, A
      Predictors for heparin resistance in patients undergoing coronary artery bypass grafting

      PERFUSION-UK
    39. Beholz, S; Grubitzsch, H; Bergmann, B; Wollert, HG; Eckel, L
      Hemostasis management by use of Hepcon/HMS (TM): Increased bleeding without increased need for blood transfusion

      THORACIC AND CARDIOVASCULAR SURGEON
    40. Poisik, A; Heyer, EJ; Solomon, RA; Quest, DO; Adams, DC; Baldasserini, CM; McMahon, DJ; Huang, J; Kim, LJ; Choudhri, TF; Connolly, ES
      Safety and efficacy of fixed-dose heparin in carotid endarterectomy

      NEUROSURGERY
    41. Coiffic, A; Cazes, E; Janvier, G; Forestier, F; Lanza, F; Nurden, A; Nurden, P
      Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the hemostatus

      THROMBOSIS RESEARCH
    42. Hashimoto, K; Sasaki, T; Hachiya, T; Takakura, H; Onoguchi, K; Nagahori, R; Takeuchi, S
      Real time measurement of heparin concentration during cardiopulmonary bypass

      JOURNAL OF CARDIOVASCULAR SURGERY
    43. Smith, CR; Spanier, TB
      Aprotinin in deep hypothermic circulatory arrest

      ANNALS OF THORACIC SURGERY
    44. Bidstrup, BP
      Assessment of heparin anticoagulation: Comparison of two commercially available methods - Invited commentary

      ANNALS OF THORACIC SURGERY
    45. Despotis, GJ; Gravlee, G; Filos, K; Levy, J
      Anticoagulation monitoring during cardiac surgery - A review of current and emerging techniques

      ANESTHESIOLOGY
    46. Coller, BS
      Potential non-glycoprotein IIb IIIa effects of abciximab

      AMERICAN HEART JOURNAL
    47. Dangas, G; Marmur, JD; King, TE; De Leon, J; Sharma, SK; Vidhun, R; Feldman, D; Stoynov, MY; Badimon, JJ; Ambrose, JA
      Effects of platelet glycoprotein IIb IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention

      AMERICAN HEART JOURNAL
    48. BELOUGNEMALFATTIE E; AGUEJOUF O; LABROUSSE L; DOUTREMEPUICH C
      A COMPARISON OF HEPARIN AND NEW ANTICOAGULANTS FOR CARDIOPULMONARY BYPASS-SURGERY

      Clinical and applied thrombosis/hemostasis
    49. PIFARRE R
      USE OF APROTININ IN THE CONTROL OF BLEEDING DURING CARDIOPULMONARY BYPASS-SURGERY - CURRENT STATUS

      Clinical and applied thrombosis/hemostasis
    50. JOBES DR
      SAFETY ISSUES IN HEPARIN AND PROTAMINE ADMINISTRATION FOR EXTRACORPOREAL-CIRCULATION

      Journal of cardiothoracic and vascular anesthesia
    51. TERAI C; SAITOH D; OKAMOTO K; KAWAKAMI M; MAGARIO N
      PLASMA ACTIVATED CLOTTING TIME AS AN INDICATOR OF DANGEROUS HYPOCOAGULABILITY IN WARFARIN-TREATED TRAUMA PATIENTS - A PRELIMINARY-STUDY

      Surgery today
    52. HEZARD N; METZ D; POTRON G; NAZEYROLLAS P; MAES D; DROULLE C; MULPAS MC; ELAERTS J; NGUYEN P
      MONITORING THE EFFECT OF HEPARIN BOLUS DURING PERCUTANEOUS CORONARY ANGIOPLASTY (PTCA) - ASSESSMENT OF 3 BEDSIDE COAGULATION MONITORS

      Thrombosis and haemostasis
    53. DOBKOWSKI WB; MURKIN JM
      A RISK-BENEFIT ASSESSMENT OF APROTININ IN CARDIAC SURGICAL-PROCEDURES

      Drug safety
    54. EHRLICH M; GRABENWOGER M; CARTESZUMELZU F; LUCKNER D; KOVARIK J; LAUFER G; KOCHER A; KONETSCHNY R; WOLNER E; HAVEL M
      OPERATIONS ON THE THORACIC AORTA AND HYPOTHERMIC CIRCULATORY ARREST -IS APROTININ SAFE

      Journal of thoracic and cardiovascular surgery
    55. FOSTER RH; WISEMAN LR
      ABCIXIMAB - AN UPDATED REVIEW OF ITS USE IN ISCHEMIC-HEART-DISEASE

      Drugs
    56. BANNAN S; MARTIN PG
      APROTININ COMPLEMENTS HEPARIN BONDING IN AN IN-VITRO MODEL OF CARDIOPULMONARY BYPASS

      British Journal of Haematology
    57. OLSON JD; ARKIN CF; BRANDT JT; CUNNINGHAM MT; GILES A; KOEPKE JA; WITTE DL
      COLLEGE-OF-AMERICAN-PATHOLOGISTS CONFERENCE XXXI ON LABORATORY MONITORING OF ANTICOAGULANT-THERAPY - LABORATORY MONITORING OF UNFRACTIONATED HEPARIN-THERAPY

      Archives of pathology and laboratory medicine
    58. CAPDEVILA X; CALVET Y; BIBOULET P; BIRON C; RUBENOVITCH J; DATHIS F
      APROTININ DECREASES BLOOD-LOSS AND HOMOLOGOUS TRANSFUSIONS IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC-SURGERY

      Anesthesiology
    59. ISCHINGER TA
      ANTITHROMBOTICS IN INTERVENTIONAL CARDIOLOGY - OPTIMIZING TREATMENT AND STRATEGIES

      The American journal of cardiology
    60. POPMA JJ; PRPIC R; LANSKY AJ; PIANA R
      HEPARIN DOSING IN PATIENTS UNDERGOING CORONARY INTERVENTION

      The American journal of cardiology
    61. PAROLARI A; ANTONA C; ALAMANNI F; SPIRITO R; NALIATO M; GEROMETTA P; ARENA V; BIGLIOLI P
      APROTININ AND DEEP HYPOTHERMIC CIRCULATORY ARREST - THERE ARE NO BENEFITS EVEN WHEN APPROPRIATE AMOUNTS OF HEPARIN ARE GIVEN

      European journal of cardio-thoracic surgery
    62. DESPOTIS GJ; LEVINE V; JOINERMAIER D; JOIST JH
      A COMPARISON BETWEEN CONTINUOUS-INFUSION VERSUS STANDARD BOLUS ADMINISTRATION OF HEPARIN BASED ON MONITORING IN CARDIAC-SURGERY

      Blood coagulation & fibrinolysis
    63. HARDY JF; BELISLE S; COUTURIER A; ROBITAILLE D
      RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND-STUDY OF AN ULTRA-LOW-DOSE APROTININ REGIMEN IN REOPERATIVE AND OR COMPLEX CARDIAC OPERATIONS/

      Journal of cardiac surgery
    64. PESOLA GR; PESOLA DA
      HEPARIN DOSING FOR PERCUTANEOUS CORONARY ANGIOPLASTY - USE OF BODY-SURFACE AREA TO IMPROVE INITIAL ACTIVATED CLOTTING TIME VALUES

      Clinical cardiology
    65. GREIBER S; WEBER U; GALLE J; BRAMER P; SCHOLLMEYER P
      ACTIVATED CLOTTING TIME IS NOT A SENSITIVE PARAMETER TO MONITOR ANTICOAGULATION WITH LOW-MOLECULAR-WEIGHT HEPARIN IN HEMODIALYSIS

      Nephron
    66. ZISMAN E; ROZENBERG B; KATZ Y; ZISER A
      A COMPARISON BETWEEN ARTERIAL-SAMPLED AND VENOUS-SAMPLED ACTIVATED CLOTTING TIME MEASUREMENTS

      Israel journal of medical sciences
    67. DESPOTIS GJ; JOIST JH; GOODNOUGH LT
      MONITORING OF HEMOSTASIS IN CARDIAC SURGICAL PATIENTS - IMPACT OF POINT-OF-CARE TESTING ON BLOOD-LOSS AND TRANSFUSION OUTCOMES

      Clinical chemistry
    68. AMMAR T; SCUDDER LE; COLLER BS
      IN-VITRO EFFECTS OF THE PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONIST C7E3 FAB ON THE ACTIVATED CLOTTING TIME/

      Circulation
    69. GERHARDT MA; GREENBERG CS; SLAUGHTER TF; SMITH MS
      FACTOR-XII DEFICIENCY AND CARDIOPULMONARY BYPASS - USE OF A NOVEL MODIFICATION OF THE ACTIVATED CLOTTING TIME TO MONITOR ANTICOAGULATION

      Anesthesiology
    70. DESPOTIS GJ; LEVINE V; FILOS KS; JOINERMAIER D; JOIST JH
      HEMOFILTRATION DURING CARDIOPULMONARY BYPASS - THE EFFECT ON ANTI-XA AND ANTI-IIA HEPARIN ACTIVITY

      Anesthesia and analgesia
    71. ZIDAR JP
      RATIONALE FOR LOW-MOLECULAR-WEIGHT HEPARIN IN CORONARY STENTING

      The American heart journal
    72. BERGELSON BA; FISHMAN RF; TOMMASO CL
      ABRUPT VESSEL CLOSURE - CHANGING IMPORTANCE, MANAGEMENT, AND CONSEQUENCES

      The American heart journal
    73. SPECK R
      NEW METHOD FOR QUANTIFYING LUPUS ANTICOAGULANT

      Clinical and applied thrombosis/hemostasis
    74. BITTL JA
      CLINICAL-TRIALS OF HIRULOG IN PATIENTS UNDERGOING HIGH-RISK PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY

      Coronary artery disease
    75. WEIGHTMAN WM; CLAPIN AOG; MICHALOPOULIS N; GIBBS NM
      SENSITIVITY AND SPECIFICITY OF THE HEMOCHRON, HEMOTEC AND APTT FOR THE DETECTION OF LOW CONCENTRATIONS OF HEPARIN

      Anaesthesia and intensive care
    76. COLLER BS; ANDERSON KM; WEISMAN HF
      THE ANTI-GPIIB-IIIA AGENTS - FUNDAMENTAL AND CLINICAL ASPECTS

      Haemostasis
    77. KUNERT M; SORGENICHT R; SCHEUBLE L; KETTELER T; LURKEN E; MEYER I; MULLER A; EMMERICH K; GULKER H
      THE ROLE OF THE ACTIVATED CLOTTING TIME ( ACT) IN ANTICOAGULATION ASSESSMENT AFTER PTCA

      Zeitschrift fur Kardiologie
    78. PITNEY MR; KELLY SA; ALLAN RM; GILES RW; MCCREDIE M; WALSH WF
      ACTIVATED CLOTTING TIME DIFFERENTIAL IS A SUPERIOR METHOD OF MONITORING ANTICOAGULATION FOLLOWING CORONARY ANGIOPLASTY

      Catheterization and cardiovascular diagnosis
    79. KNUDSEN L; HASENKAM JM; KURE HH; HUGHES P; BELLAICHE L; AHLBURG P; DJURHUUS C
      MONITORING THROMBIN GENERATION WITH PROTHROMBIN FRAGMENT-1.2 ASSAY DURING CARDIOPULMONARY BYPASS-SURGERY

      Thrombosis research
    80. RYU KH; HINDMAN BJ; REASONER DK; DEXTER F
      HEPARIN REDUCES NEUROLOGICAL IMPAIRMENT AFTER CEREBRAL ARTERIAL AIR-EMBOLISM IN THE RABBIT

      Stroke
    81. WHALEN J; TUMAN KJ
      MONITORING HEMOSTASIS

      International anesthesiology clinics
    82. DESPOTIS GJ; ALSOUFIEV AL; SPITZNAGEL E; GOODNOUGH LT; LAPPAS DG
      RESPONSE OF KAOLIN ACT TO HEPARIN - EVALUATION WITH AN AUTOMATED-ASSAY AND HIGHER HEPARIN DOSES

      The Annals of thoracic surgery
    83. HENDRICE C; SCHMARTZ D; PRADIER O; CORON T; KUCHARCEZWSKI C; DHOLLANDER A; CAPEL P
      EFFECTS OF APROTININ ON BLOOD-LOSS, HEPARIN MONITORING TESTS, AND HEPARIN DOSES IN PATIENTS UNDERGOING CORONARY-ARTERY BYPASS-SURGERY

      Journal of cardiothoracic and vascular anesthesia
    84. FERGUSON JJ; DOHMEN P; WILSON J; VAUGHN WK; KHOSHNEVIS R; KMONICEK P; MCKINNEY AA; PLACHETKA JR
      RESULTS OF A NATIONAL SURVEY ON ANTICOAGULATION FOR PTCA

      The Journal of invasive cardiology
    85. DORMAN BH; ELLIOTT BM; SPINALE FG; BAILEY MK; WALTON JS; ROBISON JG; BROTHERS TE; COOK MH
      PROTAMINE USE DURING PERIPHERAL VASCULAR-SURGERY - A PROSPECTIVE RANDOMIZED TRIAL

      Journal of vascular surgery
    86. TURRI F; DELLAVOLPE A; LEIRNER AA
      CLINICAL COMPARISON OF BLOOD OXYGENATORS - A RETROSPECTIVE STUDY

      Artificial organs
    87. BLUMENTHAL RS; CARTER AJ; RESAR JR; COOMBS V; GLOTH ST; DALAL J; BRINKER JA
      COMPARISON OF BEDSIDE AND HOSPITAL LABORATORY COAGULATION STUDIES DURING AND AFTER CORONARY INTERVENTION

      Catheterization and cardiovascular diagnosis
    88. GOLDSTEIN DJ; DEROSA CM; MONGERO LB; WEINBERG AD; MICHLER RE; ROSE EA; OZ MC; SMITH CR
      SAFETY AND EFFICACY OF APROTININ UNDER CONDITIONS OF DEEP HYPOTHERMIAAND CIRCULATORY ARREST

      Journal of thoracic and cardiovascular surgery
    89. JOBES DR; AITKEN GL; SHAFFER GW
      INCREASED ACCURACY AND PRECISION OF HEPARIN AND PROTAMINE DOSING REDUCES BLOOD-LOSS AND TRANSFUSION IN PATIENTS UNDERGOING PATIENTS CARDIACOPERATIONS

      Journal of thoracic and cardiovascular surgery
    90. DAVIS R; WHITTINGTON R
      APROTININ - A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC EFFICACY IN REDUCING BLOOD-LOSS ASSOCIATED WITH CARDIAC-SURGERY

      Drugs
    91. LEVY JH; PIFARRE R; SCHAFF HV; HORROW JC; ALBUS R; SPIESS B; ROSENGART TK; MURRAY J; CLARK RE; SMITH P; NADEL A; BONNEY SL; KLEINFIELD R
      A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF APROTININ FOR REDUCING BLOOD-LOSS AND THE REQUIREMENT FOR DONOR-BLOOD TRANSFUSION IN PATIENTS UNDERGOING REPEAT CORONARY-ARTERY BYPASS-GRAFTING

      Circulation
    92. DIETRICH W; DILTHEY G; SPANNAGL M; JOCHUM M; BRAUN SL; RICHTER JA
      INFLUENCE OF HIGH-DOSE APROTININ ON ANTICOAGULATION, HEPARIN REQUIREMENT, AND CELITE-ACTIVATED AND KAOLIN-ACTIVATED CLOTTING TIME IN HEPARIN-PRETREATED PATIENTS UNDERGOING OPEN-HEART-SURGERY - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

      Anesthesiology
    93. JANSSEN MJFM; HUIJGENS PC; BOUMAN AA; OE PL; VANDERMEULEN J
      CITRATE ANTICOAGULATION AND DIVALENT-CATIONS IN HEMODIALYSIS

      Blood purification
    94. SHIMADA M; MATSUMATA T; TAKETOMI A; NISHIZAKI T; ITASAKA H; SUGIMACHI K
      MAJOR HEPATIC RESECTION IN PATIENTS WITH A PROSTHETIC HEART-VALVE RECEIVING ANTICOAGULATION TREATMENT

      Hepato-gastroenterology
    95. FEINDT P; SEYFERT UT; VOLKMER I; STRAUB U; GAMS E
      CELITE AND KAOLIN PRODUCE DIFFERING ACTIVATED CLOTTING TIMES DURING CARDIOPULMONARY BYPASS UNDER APROTININ THERAPY

      The thoracic and cardiovascular surgeon
    96. WARNER MF; MIAN MS; MISSRI JC
      ACTIVATED CLOTTING-TIME VARIABILITY IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY

      Clinical cardiology
    97. CALIFF RM; SHADOFF N; VALETT N; BATES E; GALEANA A; KNOPF W; SHAFTEL J; BENDER MJ; AVERSANO T; RAQUENO J; GURBEL P; COWFER J; COHEN M; CROSS P; BITTL J; EDDINGS K; TAYLOR M; DEROSA K; HATTEL L; COOPER L; ESHELMAN B; FINTEL D; NIEMYSKI P; KLEIN L; KENNEDY H; THORNTON T; KEREIAKES D; MARTIN L; ANDERSON L; HIGBY N; ELLIS S; BREZINA K; GEORGE B; CHAPEKIS A; SMITH D; ANWAR A; GERBER TL; PRITCHARD GL; MYLER R; SHAW R; MURPHY M; WARD K; MADIGAN NP; BLANKENSHIP J; HALBERT M; FLANAGAN C; TANNENBAUM M; POLICH M; STEVENSON C; TCHENG J; HOFFMAN S; MOORE RM; SMITH J; HENRY P; MCDONOUGH TJ; WESZT S; BRODIE B; MUNCY D; KLEIMAN N; TRAINOR K; ROSE D; JOHNSON S; WILLERSON J; FERGUSON JJ; HARLAN M; BASS TA; ROHMAN G; BROWNE K; CIESLA C; WORLEY S; TUZI J; HETTLEMAN B; BURKE WC; OLSEN G; KENNEDY SJ; TALLEY JD; YUSSMAN ZA; RAWERT M; GRASSMAN ED; WRONA L; SAMAHA J; EHEMANN B; BLEICH SD; LEONHARD R; CUMMINS F; NONNWEILER J; SANZ M; MAYER D; CLEMAN MW; PASCALE VJ; MCCONNELL S; DELCORE M; STENGEL L; IVANHOE RJ; GRANGER N; ROSENBERG MJ; SCHAECHTER A; AYCOCK G; WILCOX T; GOTTLIEB R; HUNTER H; UNTERECKER W; HART B; HEUSER R; HOOPMANN S; HANOVICH G; ANTOLICK A; GACIOCH G; CHIODO V; KARSKI K; TIMMIS G; SAFIAN M; AGUIRRE F; STONNER T; TAYLOR GJ; WOMACK K; RUYLE B; KRAUTHAMER D; WELCOM G; WESTON M; DILLON K; FRENCH WJ; REYNOLDS GT; NAVETTA F; MURPHY G; LEBOEUF R; SPENCER S; POPMA JJ; SWEET L; TOPOL EJ; SMITH CR; WEISMAN H; LEE KL; MILLER J; SIGMON K; TCHENG J; LEE KL; LUI M; KOSLOFF A; DIFULVIO J; WANG AL; ANDERSON K; WEISMAN H; DANN R; KINGMA W; NORTON D; MYER B; MASEK R; LEWANDOWSKI M; BRODERICK S; MUSCO M; SCHORR M; HARTMAN P; MCCARDLE L; FAXON D; ARMSTRONG P; GORE J; LOSCALZO J; MCCULLOUGH L; VERTER J; MARK DB; DAVIDSONRAY L; CLAPPCHANNING N; LAM LC; WAUGH RA; MCCANTS CB; HINDMAN MC; DEHMER G; HILLEGASS WB; FRID DJ; FORTIN DF; BROTT BC; FOREST TL; UNKS DM; HAMER ME; WAGNER GS; GATES K; SANE D
      USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY/

      The New England journal of medicine
    98. LEMMER JH; STANFORD W; BONNEY SL; BREEN JF; CHOMKA EV; ELDREDGE WJ; HOLT WW; KARP RB; LAUB GW; LIPTON MJ; SCHAFF HV; TATOOLES CJ; RUMBERGER JA
      APROTININ FOR CORONARY-BYPASS OPERATIONS - EFFICACY, SAFETY, AND INFLUENCE ON EARLY SAPHENOUS-VEIN GRAFT PATENCY - A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

      Journal of thoracic and cardiovascular surgery
    99. COYNE TJ; WALLACE MC; BENEDICT C
      PERIOPERATIVE ANTICOAGULANT EFFECTS OF HEPARINIZATION FOR CAROTID ENDARTERECTOMY

      Australian and New Zealand journal of surgery
    100. TABUCHI N; NJO TL; TIGCHELAAR I; HUYZEN RJ; BOONSTRA PW; VANOEVEREN W
      MONITORING OF ANTICOAGULATION IN APROTININ-TREATED PATIENTS DURING HEART OPERATION

      The Annals of thoracic surgery


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/05/20 alle ore 03:33:17